bioAffinity TechnologiesBIAF -1.48%44 Quick Ratio is 1.34 as of Mar. 2026, which is at its 10-year median of 1.34. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, bioAffinity Technologies ranks worse than 61.21% on this metric.
bioAffinity Technologies has a quick ratio of 1.34. It generally indicates good short-term financial strength.
The historical rank and industry rank for bioAffinity Technologies's Quick Ratio or its related term are showing as below:
BIAF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1.34 Max: 12.84
Current: 1.34
During the past 6 years, bioAffinity Technologies's highest Quick Ratio was 12.84. The lowest was 0.01. And the median was 1.34.
BIAF's Quick Ratio is ranked worse than 61.21% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.735
vs BIAF: 1.34
bioAffinity Technologies (NAS:BIAF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
bioAffinity Technologies Quick Ratio Related Terms
bioAffinity Technologies Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, bioAffinity Technologies's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Quick Ratio distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
bioAffinity Technologies's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a Quick Ratio of 1.34 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on bioAffinity Technologies and its competitors. This is near median its historical median of 1.34. Over the past decade, bioAffinity Technologies' Quick Ratio has ranged from 0.01 to 12.84. According to the industry distribution chart, bioAffinity Technologies ranks #131 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 61.2%.
Is bioAffinity Technologies' Quick Ratio too high?
bioAffinity Technologies' current Quick Ratio of 1.34 is near median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 12.84. The Medical Diagnostics & Research industry median Quick Ratio is 1.74. bioAffinity Technologies' value of 1.34 is 22.8% below this industry median. Based on the distribution chart, bioAffinity Technologies ranks #131 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Quick Ratio compare to NDRA and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #131 out of 214 companies for Quick Ratio. This places bioAffinity Technologies in the lower half of its industry. The industry median Quick Ratio is 1.74. bioAffinity Technologies' value of 1.34 is 22.8% below this benchmark. Historically, bioAffinity Technologies' own Quick Ratio has ranged from 0.01 to 12.84 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 1.74, bioAffinity Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.74, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current Quick Ratio of 1.34 is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Quick Ratio is 1.34, which is near median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current Quick Ratio is 1.34, which is near median its 10-year median of 1.34 and 22.8% below the Medical Diagnostics & Research industry median of 1.74. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Quick Ratio is 1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
Quick Ratio: 1.34 (near median its 10-year median of 1.34)
GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
Industry Position: 22.8% below the Medical Diagnostics & Research median (#131 of 214)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
